Group One Trading
RXRX icon

Group One Trading’s Recursion Pharmaceuticals RXRX Stock Holding History

Group One Trading’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.79M Sell
582,000
-1,392,800
-71% -$5.38M ﹤0.01% 2183
2025
Q4 		$8.08M Buy
1,974,800
+898,800
+84% +$4.45M 0.01% 1094
2025
Q3 		$5.25M Sell
1,076,000
-325,400
-23% -$1.71M 0.01% 1439
2025
Q2 		$7.09M Buy
1,401,400
+240,300
+21% +$1.18M 0.02% 1055
2025
Q1 		$6.14M Buy
1,161,100
+51,000
+5% +$372K 0.02% 922
2024
Q4 		$7.5M Buy
1,110,100
+906,500
+445% +$6.09M 0.02% 872
2024
Q3 		$1.34M Sell
203,600
-81,500
-29% -$584K ﹤0.01% 2064
2024
Q2 		$2.14M Sell
285,100
-3,300
-1% -$28.8K 0.01% 1399
2024
Q1 		$2.88M Buy
288,400
+22,400
+8% +$249K 0.01% 1222
2023
Q4 		$2.62M Buy
266,000
+138,000
+108% +$984K 0.01% 1643
2023
Q3 		$979K Buy
128,000
+127,000
+12,700% +$1.27M ﹤0.01% 2286
2023
Q2 		$7.47K Sell
1,000
-4,400
-81% -$30.8K ﹤0.01% 6542
2023
Q1 		$36K Buy
5,400
+400
+8% +$3.17K ﹤0.01% 5101
2022
Q4 		$38.5K Buy
+5,000
New +$49K ﹤0.01% 5188

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Group One Trading's RXRX Position: Q1 2026 in Review

Group One Trading opened a new position in Recursion Pharmaceuticals (RXRX) in Q1 2026: 901,111 shares worth $2.77M. The stake represents 0.01% of the portfolio and ranks #1782 among its holdings. This is a return to the name: Group One Trading previously reported a position in RXRX as recently as Q3 2025.

Group One Trading first reported a position in RXRX in Q3 2022 and has held it in 10 quarters since. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Group One Trading held 901,111 shares of Recursion Pharmaceuticals worth $2.77M as of Q1 2026.
  • Recursion Pharmaceuticals was a new Group One Trading position in Q1 2026.
  • Recursion Pharmaceuticals made up 0.01% of Group One Trading's portfolio in Q1 2026, its #1782 holding.
  • Group One Trading first reported a position in Recursion Pharmaceuticals in Q3 2022 and has held it in 10 quarters since.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.